Fundraising Fox
Proxygen GmbH
36 employees on LinkedIn · 1 known investors
Find your way into Proxygen GmbH
Sign up to see every warm intro you have to Proxygen GmbH
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Proxygen GmbH team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Proxygen discovers glue degraders, a novel drug modality that targets protein interactions for therapeutic treatments. The company uses protein science and molecular approaches to develop new treatments for disease.
Founders & leadership
GS
Giulio Superti-FurgaCo-FounderFounder of Proxygen, which discovers glue degraders — a drug modality targeting protein interactions for therapeutic treatments. He has led biomedical research organizations in both industry and academia and is establishing a research institute focused on metabolism, with expertise spanning systems biology, systems and network medicine, drug discovery, proteomics, and the management of research institutions and companies.
Investors · 1
Frequently asked questions
- What does Proxygen GmbH do?
- Proxygen discovers glue degraders, a novel drug modality that targets protein interactions for therapeutic treatments. The company uses protein science and molecular approaches to develop new treatments for disease.
- Who founded Proxygen GmbH?
- Proxygen GmbH was founded by Giulio Superti-Furga.
- Who are Proxygen GmbH's investors?
- Proxygen GmbH's investors include Wlanholding.